Stock Scorecard
Stock Summary for Exelixis Inc (EXEL) - $42.57 as of 12/19/2025 2:52:46 PM EST
Total Score
13 out of 30
Safety Score
43 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for EXEL
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for EXEL
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for EXEL
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for EXEL
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for EXEL (43 out of 100)
| Stock Price Rating (Max of 10) | 8 |
| Historical Stock Price Rating (Max of 10) | 6 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 4 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 6 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for EXEL
Financial Details for EXEL
Company Overview |
|
|---|---|
| Ticker | EXEL |
| Company Name | Exelixis Inc |
| Country | N/A |
| Description | Exelixis, Inc. is a prominent biotechnology firm based in Alameda, California, focused on the discovery and commercialization of innovative oncology therapies. Boasting a robust portfolio of approved drugs alongside a promising pipeline, Exelixis is strategically positioned to tackle substantial unmet needs in cancer treatment. The company's dedication to enhancing patient outcomes through cutting-edge research and development underpins its role as a significant contributor to the biopharmaceutical landscape. By relentlessly pursuing transformative cancer solutions, Exelixis aims to deliver meaningful value to both patients and investors. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 42.57 |
| Price 4 Years Ago | 18.28 |
| Last Day Price Updated | 12/19/2025 2:52:46 PM EST |
| Last Day Volume | 5,241,674 |
| Average Daily Volume | 2,601,240 |
| 52-Week High | 49.62 |
| 52-Week Low | 31.90 |
| Last Price to 52 Week Low | 33.45% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 56.90 |
| Sector PE | 53.39 |
| 5-Year Average PE | 24.54 |
| Free Cash Flow Ratio | 30.41 |
| Industry Free Cash Flow Ratio | 22.58 |
| Sector Free Cash Flow Ratio | 33.77 |
| Current Ratio Most Recent Quarter | 3.75 |
| Total Cash Per Share | 1.40 |
| Book Value Per Share Most Recent Quarter | 8.06 |
| Price to Book Ratio | 5.16 |
| Industry Price to Book Ratio | 52.55 |
| Sector Price to Book Ratio | 49.15 |
| Price to Sales Ratio Twelve Trailing Months | 4.94 |
| Industry Price to Sales Ratio Twelve Trailing Months | 18.91 |
| Sector Price to Sales Ratio Twelve Trailing Months | 14.97 |
| Analyst Buy Ratings | 9 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 268,112,000 |
| Market Capitalization | 11,413,527,840 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 2.47% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 72.50% |
| Annual Earnings Growth | 150.89% |
| Reported EPS 12 Trailing Months | 2.40 |
| Reported EPS Past Year | 2.15 |
| Reported EPS Prior Year | 1.92 |
| Net Income Twelve Trailing Months | 677,903,000 |
| Net Income Past Year | 521,267,000 |
| Net Income Prior Year | 207,765,000 |
| Quarterly Revenue Growth YOY | 10.80% |
| 5-Year Revenue Growth | 17.51% |
| Operating Margin Twelve Trailing Months | 42.90% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 376,300,000 |
| Total Cash Past Year | 217,374,000 |
| Total Cash Prior Year | 262,994,000 |
| Net Cash Position Most Recent Quarter | 376,300,000 |
| Net Cash Position Past Year | 217,374,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 2,244,203,000 |
| Total Stockholder Equity Prior Year | 2,263,912,000 |
| Total Stockholder Equity Most Recent Quarter | 2,160,700,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 749,516,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 2.80 |
| Free Cash Flow Past Year | 633,786,000 |
| Free Cash Flow Prior Year | 170,355,000 |
Options |
|
| Put/Call Ratio | 0.65 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 35.92 |
| 20-Day Bollinger Middle Band | 40.00 |
| 20-Day Bollinger Upper Band | 44.09 |
| Beta | 0.40 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 12/19/2025 10:37:50 PM EST |